Selected Publications
Burkhart RA, Relles D, Pineda DM, Gabale S, Sauter PK, Rosato EL, Koniaris LG, Lavu H, Kennedy EP, Yeo CJ, Winter JM. Defining treatment and outcomes of hepaticojejunostomy failure following pancreaticoduodenectomy. J Gastrointest Surg. 2013 Mar;17(3):451-60.
Burkhart RA, Peng Y, Norris ZA, Tholey R, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Molecular Cancer Research. 2013 Aug;11(8):901-11.
Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biology. 2013 Aug 1;10(8):1312-23.
Burkhart RA, Tholey RM, Guinto D, Yeo CJ, Chojnacki K. Grit: A marker for residents at risk for attrition? Surgery. 2014 Jun; 155(6): 1014-22.
Burkhart RA, Gerber SM, Tholey RM, Lamb K, Somasundaram A, McIntyre C, Fradkin E, Ashok A, Felte R, Mehta J, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, Winter JM. Incidence and severity of pancreatogenic diabetes after pancreatic resection. J Gastrointest Surg. 2015 Feb; 19(2): 217-25.
Burkhart RA, Laheru D, Herman J, Pawlik T. Multidisciplinary management and the future of treatment in cholangiocarcinoma. Expert Opinion on Orphan Drugs. 2016 Mar; 4(3): 255-67.
Burkhart RA, Pawlik TM. Personalized therapy in hepatocellular carcinoma: molecular markers of prognosis and therapeutic response. Surgical Oncology. 2017 Jun; 26(2): 138-145.
Burkhart RA, Javed AA, Ronnekleiv-Kelly S, Wright MJ, Poruk KE, Eckhauser F, Makary MA, Cameron JL, Wolfgang CL, He J, Weiss MJ. The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. HPB. 2017 Jun; [EPUB]
Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017 Jul 25. [EPUB]